DR. EUGENE ANTHONY WOLTERING, MD
Radiology at Esplanade Ave, Kenner, LA

7709031, May 4, 2010

May 27, 2004

10/559091

Frank L. Greenway - Baton Rouge LA, US
Zhijun Liu - Baton Rouge LA, US
Eugene A. Woltering - Kenner LA, US

Board of Supervisors of Louisiana State University And Agricultural and Mechanical College - Baton Rouge LA

A61K 36/00, A61K 51/00, A61K 39/395, A61K 38/21

424725, 424 169, 4241451, 424 854

An extract of Chinese blackberry () has been found to inhibit angiogenesis, and two active fractions isolated. Gallic acid was shown to be one of the active anti-angiogenic compounds by an in vitro human angiogenesis model. Aqueous extracts from other plants either known or found to have gallic acid were also found to have anti-angiogenic activity. Various derivatives of gallic acid were found to inhibit angiogenesis. The extract from Chinese blackberry also slowed the growth of a pancreatic tumor and of corneal neovascularization in rats. Extracts from pomegranate were shown to inhibit angiogenesis in fat tissue. Extracts from spp, and other plants with gallic acid, and gallic acid and its derivatives will be useful for treating various diseases associated with neovascularization, including diabetic retinopathy, psoriasis, tumors, obesity, cancer, rheumatoid arthritis, etc.

8012517, Sep 6, 2011

Aug 30, 2002

10/488176

Eugene A. Woltering - Kenner LA, US
Conrad A. Hornick - New Orleans LA, US
Amy E. Myers - New Orleans LA, US

Board of Supervisors of Louisiana State University And Agricultural and Mechanical College - Baton Rouge LA

A01N 65/00

424769, 424777

Noni juice and a protein-free, alcohol precipitate of Noni juice inhibited angiogenesis in in vitro human angiogenesis models. When growth medium contained Noni juice at least over the range from about 2. 5% to about 33% (by volume), angiogenesis was blocked. Moreover, Noni juice and an ethanol precipitate were able to destroy a pre-existing angiogenic response as well as prevent the development of new vessels. Noni juice was effective in inhibiting the growth of angiogenic vessels from breast cancer explants. It will also be effective in treating cancers and non-cancerous diseases whose response includes an increase in angiogenesis, e. g. , retinopathy of prematurity, neovascular glaucoma, diabetic retinopathy, and psoriasis. The primary antiangiogenic component is believed to be a carbohydrate with a molecular weight less than about 6000 Daltons. In an initial experiment, oral administration of Noni juice appeared to adversely affect the antioangiogenic component(s) in the juice.

7427662, Sep 23, 2008

Feb 1, 2005

11/047852

Conrad A. Hornick - New Orleans LA, US
Eugene A. Woltering - Kenner LA, US

Baord of Supervisors of Louisiana State University And Agricultural and Mechanical College - Baton Rouge LA

C07K 14/435

530359, 530350, 514 2

Apolipoprotein A-I-rich Lhigh-density Lipoprotein 2 (HDL2) and Apolipoprotein A-I (ApoA-I) was discovered to inhibit angiogenesis in an in vitro human angiogenesis model, the human placental vein angiogenesis model. Apolipoprotein A-I was able to destroy a pre-existing angiogenic response as well as prevent the development of new vessels. Application of Apolipoprotein A-I will be effective in inhibiting tumor growth dependent on angiogenesis, and in decreasing existing blood vessels formed by tumors. It will also be effective in treating non-cancerous diseases which symptoms include an increase in angiogenesis, e. g. , psoriasis, retinopathy of prematurity, neovascular glaucoma, diabetic retinopathy, obesity, and psoriasis.

7381400, Jun 3, 2008

Jul 13, 2004

10/890420

Eugene A. Woltering - Kenner LA, US

Board of Supervisors of Louisiana State University And Agricultural and Mechanical College - Baton Rouge LA

A61K 49/00

424 91, 424 111, 424 165, 424 181, 424 185, 424 189

A one-step procedure for sentinel lymph node identification and biopsy using a single compound, a radiolabeled, low molecular weight dye (e. g. , I-labeled methylene blue). This radiolabled dye is mixed with an unlabeled, similar molecular weight dye (e. g. , isosulfan or methylene blue). The mixture is injected at the time of surgery, and rapidly migrates to reach the lymph nodes in less than 20 min, more preferably in less than 15 min and most preferably in less than 10 min. Using rabbits, rapid transit of I-methylene blue to regional lymph nodes with limited systemic biodistribution has been confirmed. By admixing small amounts of radiolabeled dye with a large amount of unlabeled dye, the sentinel lymph node identification was similar to that for the prior two-step dual mapping process, but with enhanced SLN localization because of the lower energy gamma emission of I as compared with Tc.

6893812, May 17, 2005

May 25, 2001

09/866296

Eugene A. Woltering - Kenner LA, US
Seza A. Gulec - New Orleans LA, US

Board of Supervisors of Louisiana State University and Agricultural and Mechanical College - Baton Rouge LA

C12Q001/00, C12N001/00, C12N001/02, C12N005/06, C12N005/08

435 4, 435 11, 435 29, 435325, 435375, 435395

An in vitro tissue angiogenesis and vasculogenesis system is disclosed that allows the outgrowth of microvessels from a three-dimensional tissue fragment implanted in a matrix. The matrix may, for example, be a fibrin- or collagen-based matrix fed by a growth medium, for example, a mixture of tissue culture medium, serum, or a layer of growth medium containing a defined mixture of growth factors. This system, which may be used with human or other mammalian or animal tissues, may be used in assaying tumor angiogenic potential, or in promoting angiogenesis in other tissues, e. g. , promoting angiogenesis prior to transplantation of a tissue. The angiogenic potential of a tissue can be determined by measuring the growth of microvessels into the matrix. The three-dimensional structure of the tumor or other tissue is maintained in the matrix, including blood vessels. In another aspect, the method allows for the proliferation of a tissue specimen, thus increasing the mass of cells available for subsequent transplant; and the method also provides for the proliferation of blood vessels from the tissue mass, thus enhancing the chance of successful engraftment.

2005020, Sep 22, 2005

May 16, 2005

11/131156

Eugene Woltering - Kenner LA, US
Seza Gulec - New Orleans LA, US

C12Q001/00

435004000

An in vitro tissue angiogenesis and vasculogenesis system is disclosed that allows the outgrowth of microvessels from a three-dimensional tissue fragment implanted in a matrix. The matrix may, for example, be a fibrin- or collagen-based matrix fed by a growth medium, for example, a mixture of tissue culture medium, serum, or a layer of growth medium containing a defined mixture of growth factors. This system, which may be used with human or other mammalian or animal tissues, may be used in assaying tumor angiogenic potential, or in promoting angiogenesis in other tissues, e.g., promoting angiogenesis prior to transplantation of a tissue. The angiogenic potential of a tissue can be determined by measuring the growth of microvessels into the matrix. The three-dimensional structure of the tumor or other tissue is maintained in the matrix, including blood vessels. In another aspect, the method allows for the proliferation of a tissue specimen, thus increasing the mass of cells available for subsequent transplant; and the method also provides for the proliferation of blood vessels from the tissue mass, thus enhancing the chance of successful engraftment.

2011016, Jul 7, 2011

Aug 14, 2009

13/058957

Zhijun Liu - Baton Rouge LA, US
Eugene A. Woltering - Kenner LA, US

ULLMAN MEDICAL, INC. - Silver Spring MD

A61K 9/12, A61K 36/00, C12Q 1/02, A61P 35/00, A61P 31/00, A61P 31/04, A61P 37/00, A61P 27/02, A61P 19/02, A61P 3/10, A61P 17/02, A61P 17/06, A61P 3/04, A61P 41/00, A61P 9/12, A61P 9/00, A61P 1/00

424 45, 424725, 435 29

The present invention is directed to methods for extracting and isolating extracts having angiogenesis inhibiting activity from a latex-containing portion of a variant, pharmaceutical and nutraceutical compositions comprising the extracts, methods of administering the extracts to treat angiogenesis-dependent diseases and to reduce or inhibit neovessel growth in a subject in need thereof, and the use of the extracts in the manufacture of a composition for reducing or inhibiting neovessel growth.

2011015, Jun 23, 2011

Mar 1, 2011

13/037989

Eugene A. Woltering - Kenner LA, US

A61K 31/427, A61P 5/20, A61P 35/00

514369, 514370

The present invention relates to a method of treating a warm-blooded animal, especially a human, having hyperparathyroidism comprising administering to said animal a therapeutically effective amount of an epothilone derivative of formula Ior a pharmaceutically acceptable salt thereof.

2006014, Jun 29, 2006

Oct 13, 2003

10/530855

Eugene Woltering - Kenner LA, US

C07D 417/02, A61K 31/427

514365000, 548181000

The present invention relates to a method of treating a warm-blooded animal, especially a human, having hyperparathyroidism comprising administering to said animal a therapeutically effective amount of an epothilone derivative of formula I or a pharmaceutically acceptable salt thereof.

2005025, Nov 17, 2005

May 13, 2004

10/845279

Eugene Woltering - Kenner LA, US

A61K049/04

424009340, 424009411

A surgical marking system has been developed that can be easily used during surgery to mark an area of the body, e.g., the margins of a tumor resection cavity, for post-operative radiation therapy or subsequent evaluation by CT, MRI, or radiography. This marker system is formed as a semi-liquid solution that is expelled into the resection margins as a stream that quickly polymerizes in situ into a solid or semi-solid strand that adheres to the surrounding tissue. Several of these strands may be placed to outline the cavity surface. One or more of the polymerizing agents contain one or more imageable markers for post-operative imaging or therapy. The method allows a surgeon to outline the margins of a surgical site in all directions. In addition, radioactive isotopes or therapeutic drugs can be added to the marker strands for in situ therapy.